• Skip to main navigation
  • Skip to main content
  • Skip to Footer
  • Navigate Novartis
    • Patients
    • Healthcare Professionals
    • Media
    • Investors
    • Partners
    • ESG
    • Job Seekers
    • Clinical Trials
  • Coronavirus
  • Global
    • Novartis site directory
Novartis logo: a global healthcare company
  • Our Company
    • Our Leadership
      • Board of Directors
      • Executive Committee of Novartis
    • Our Approach
      • Strategy
      • Corporate Responsibility
      • Diversity & Inclusion
      • Partnering
      • People and Culture
    • Our Business
      • Global Product Portfolio
      • Innovative Medicines
      • Novartis Pharmaceuticals
      • Novartis Gene Therapies
      • Novartis Oncology
      • Sandoz
    • Media
      • Newsroom
      • News Archive
      • Multimedia Resources
      • Subscribe to Updates
    • Investors
      • Event Calendar
      • Financial Data
      • Share Data & Analysis
      • Shareholder Information
      • Environmental, Social & Governance
  • Our Focus
    • Disease Areas
      • Cancer
      • Cardiovascular, Renal and Metabolic Medicine
      • Immunology & Dermatology
      • Ophthalmology
      • Neuroscience
      • Respiratory
    • Platforms and Technology
      • Data and Digital
      • Cell & Gene Therapy
    • Novartis Stories
      • Discovery
      • From Our Labs
      • Access to Healthcare
      • Patient Perspectives
      • People and Culture
      • Live Magazine
  • Our Impact
    • Building Trust with Society
      • Corporate Responsibility
      • Ethical Standards
      • Access
      • Environmental Sustainability
    • Global Health
      • Malaria
      • Sickle Cell Disease
      • Chagas disease
      • Leprosy
      • Novartis Foundation
    • ESG Performance and Reporting
      • Materiality Assessment
      • Environmental, Social and Governance
      • Transparency and Disclosures
      • Positions on Key Topics
      • Statements on Key Issues
  • Our Science
    • Research & Early Development
      • Novartis Institutes for BioMedical Research
      • Research Disease Areas
      • Postdoc Program
      • Open Source Science
    • Drug Development at Novartis
      • Novartis Pipeline
      • Clinical Trials
      • Translational Medicine
      • Global Product Portfolio
    • Science Stories
      • Discovery
      • From Our Labs
  • Careers
    • Your Career
      • Global Career Search
      • Teams and Skills
      • Gene Therapies Careers
    • Working at Novartis
      • Diversity & Inclusion
      • People and Culture
      • Corporate Responsibility
    • Career Programs
      • Our Career Programs
      • Students and Scholars
      • Novartis Quantitative Sciences Hackathon
Search
Healthcare worker, Dismus Mwalukwanda, discussing with a group of people in a rural part of Zambia
  • TwitterTweet
  • FacebookShare
  • Share
    • Twitter
    • Facebook
    • LinkedIn
    • Email
    • Whatsapp
  • Jump to Comments
Stories/Access to Healthcare

Malaria fighter rides bicycle into battle with disease

Healthcare worker Dismus Mwalukwanda is on the front line of the battle against malaria. Saving lives is his priority

Sep 10, 2015

Dismus Mwalukwanda works on the front line of the battle against malaria, one of the world’s deadliest diseases. He’s a community healthcare worker responsible for testing and treating patients in a remote part of rural Zambia, as well as teaching people how to combat the illness. 

Although malaria caused an estimated 584,000 deaths in 2013, mostly among African children, efforts to fight the disease are having an impact. World Health Organization figures show that malaria deaths dropped 47% between 2000 and 2013. 

Progress against the disease is thanks to a variety of factors, including the hard work of countless people like Dismus, who use rapid diagnostic tests and malaria treatments to care for people. It’s also due to greater availability of insecticide-treated bed nets that protect people from being bitten by malaria-carrying mosquitos, as well as increased collaboration among the many governments, companies and non-government organizations fighting the disease. 

As part of that fight, Novartis supplies antimalarial medicine at no profit to public health systems and supports health workers in their efforts against the disease through malaria education programs. Between 2012 and 2014, Novartis helped more than 17,000 health workers in Kenya, Ethiopia, Nigeria and Uganda with training.  

Listen to Dismus talk about the challenges he faces in his work fighting malaria in this audio slideshow featuring images taken by award-winning photographer Brent Stirton.  

Tags: 
Access to Healthcare, Disease Eradication, Infectious Diseases, Malaria, Novartis Social Business, Tropical Diseases
    • TwitterTweet
    • FacebookShare
    • Share
      • Twitter
      • Facebook
      • LinkedIn
      • Email
      • Whatsapp
    • Jump to Comments
  • Print
  • Save

Novartis Stories

View all

Dr. Theophile Tuyisabe standing next to his patients smiling at him
Access to Healthcare

Meet a visionary who beat the odds to realize his vision of inclusive eye care

Access to Healthcare

Chagas disease: Breaking the silence

Sandoz in Kalwe, India ensures multidrug therapy (MTD) supply to WHO to fight leprosy
Access to Healthcare

Ensuring medicine supply to patients during COVID-19

You are here

  1. Home ›
  2. Stories ›
  3. Access healthcare

Novartis Global

  • Navigate Novartis

    • Patients & Caregivers
    • Healthcare Professionals
    • Investors
    • Media
    • Society & ESG
    • Partners
  • Contact Us

    • Global Contacts
    • Office Locations
    • For Investors
    • For Media
  • About Novartis

    • Our Company
    • Our Focus
    • Our Impact
    • Our Science
    • Our Stories
  • Our Portfolio

    • Global Product Portfolio
    • Global Clinical Pipeline
  • Careers

    • Career Search

Connect with Novartis

  • twitter
  • linkedin
  • youtube
  • facebook
  • instagram
Novartis Site Directory
© 2021 Novartis AG
  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Site Map
  • Cookie Settings

This site is intended for a global audience.